| Name | Title | Contact Details |
|---|
Corporate Fleet Services specializes in the acquisition and sale of corporate jets. We have successfully completed hundreds of transactions Nationally and Internationally. It is rare that a Dealer can inventory the large corporate jets required in todays business environment. Few are in the position to structure the leasing, purchasing or delayed purchase options we offer. In addition to purchasing and selling aircraft, Corporate Fleet Services can act as your exclusive agent to either purchase or sell your current aircraft. Our research department is updating its files daily to stay ahead of market trends.
ChefStable partners with chefs to design, build and operate restaurants. We invest in chefs we believe in, chefs who have shown a commitment to their craft and whose food reflects their passion and talent. We take care of all of the operational details which allows our partners to focus on whats truly important: food and service.
Located in Nashville, TN, Paladin capital is a premier leader in business acquisition, and ownership transfer, via Employee Stock Ownership Plans (ESOP). Paladins mission is to provide employee ownership and retirement benefits to to the employees of the sellers company while providing private business owners a meaningful exit strategy that preserves their business legacy.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Accelerant is a data-driven risk exchange connecting specialty insurance underwriters with risk capital providers. Founded in 2018 by a group of longtime insurance industry executives and technology experts, our vision is to rebuild the way risk is exchanged – so that it works better, for everyone. For the underwriters we call Members, we deliver a full service offering that includes insights and analytics, distribution management, operational resources, and stable underwriting capacity. Our approach frees our Members to focus on profitable underwriting while growing their businesses. Our portfolio presents attractive, validated, and diversified source of specialty insurance premium to our risk capital provider partners.